Symptomzentrierte Ansicht
Unvollständige Wirkung des Arzneimittels
Substanzen, die Unvollständige Wirkung des Arzneimittels disproportional melden — sortiert nach ROR.
148 von 148 angezeigt
| Substanz ↓ | ROR [95% CI] | Meldungen | Kategorie | Fachinformation |
|---|---|---|---|---|
| 13.0 [10.7–15.7] | 111 | algemeen | neu | |
| 37.1 [32.2–42.8] | 213 | algemeen | neu | |
| 22.0 [19.2–25.3] | 216 | algemeen | neu | |
| 7.1 [4.4–11.7] | 16 | algemeen | neu | |
| 16.8 [12.3–22.8] | 43 | algemeen | neu | |
| 8.4 [7.3–9.6] | 196 | algemeen | neu | |
| 6.9 [6.3–7.5] | 556 | algemeen | neu | |
| 3.8 [3.5–4.0] | 956 | algemeen | neu | |
| 7.1 [6.0–8.4] | 132 | algemeen | neu | |
| 11.3 [11.0–11.6] | 6.288 | algemeen | neu | |
| 17.0 [15.6–18.5] | 580 | algemeen | neu | |
| 9.3 [9.0–9.6] | 4.320 | algemeen | neu | |
| 11.0 [10.0–12.1] | 434 | algemeen | neu | |
| 11.0 [10.0–12.1] | 434 | algemeen | neu | |
| 17.9 [14.4–22.3] | 86 | algemeen | neu | |
| 21.8 [18.2–26.2] | 123 | algemeen | neu | |
| 4.0 [2.5–6.4] | 18 | algemeen | neu | |
| 2.5 [1.9–3.4] | 49 | algemeen | neu | |
| 34.7 [30.1–40.0] | 215 | algemeen | neu | |
| 9.8 [8.2–11.7] | 124 | algemeen | neu | |
| 22.7 [19.8–26.0] | 221 | algemeen | neu | |
| 10.3 [7.8–13.5] | 52 | algemeen | neu | |
| 10.4 [10.1–10.7] | 5.054 | algemeen | neu | |
| 9.2 [8.8–9.7] | 1.982 | algemeen | neu | |
| 7.1 [6.0–8.3] | 155 | algemeen | neu | |
| 3.5 [3.3–3.7] | 1.095 | algemeen | neu | |
| 3.8 [3.6–4.0] | 961 | algemeen | neu | |
| 16.5 [15.3–17.9] | 643 | algemeen | neu | |
| 6.3 [3.7–10.8] | 14 | algemeen | neu | |
| 3.9 [2.9–5.3] | 43 | algemeen | neu | |
| 7.4 [7.2–7.6] | 10.438 | algemeen | neu | |
| 6.0 [4.7–7.7] | 63 | algemeen | neu | |
| 11.6 [8.7–15.5] | 48 | algemeen | neu | |
| 5.5 [3.8–7.9] | 29 | algemeen | neu | |
| 22.0 [18.6–26.1] | 143 | algemeen | neu | |
| 15.5 [12.9–18.6] | 122 | algemeen | neu | |
| 7.6 [5.2–11.1] | 28 | algemeen | neu | |
| 5.4 [4.4–6.7] | 86 | algemeen | neu | |
| 37.8 [32.8–43.6] | 213 | algemeen | neu | |
| 37.8 [32.8–43.6] | 213 | algemeen | neu | |
| 37.8 [32.8–43.6] | 213 | algemeen | neu | |
| 37.8 [32.8–43.6] | 213 | algemeen | neu | |
| 2.8 [2.6–3.1] | 713 | algemeen | neu | |
| 6.2 [5.8–6.6] | 1.077 | algemeen | neu | |
| 6.6 [5.4–8.1] | 99 | algemeen | neu | |
| 5.5 [4.6–6.7] | 108 | algemeen | neu | |
| 6.0 [5.3–6.7] | 291 | algemeen | neu | |
| 6.0 [5.3–6.7] | 291 | algemeen | neu | |
| 8.7 [7.5–10.1] | 176 | algemeen | neu | |
nicotinamide Niacinamide | 42.3 [37.5–47.8] | 300 | longevity | neu |
| 16.9 [14.8–19.3] | 226 | algemeen | neu | |
| 7.6 [6.6–8.7] | 210 | algemeen | neu | |
| 6.5 [5.7–7.5] | 212 | algemeen | neu | |
| 11.7 [10.4–13.2] | 284 | algemeen | neu | |
| 20.0 [16.7–24.0] | 126 | algemeen | neu | |
| 7.3 [6.5–8.2] | 320 | algemeen | neu | |
| 7.3 [6.5–8.1] | 320 | algemeen | neu | |
| 8.9 [8.5–9.2] | 3.313 | algemeen | neu | |
| 7.2 [6.9–7.4] | 3.869 | algemeen | neu | |
| 5.4 [5.1–5.7] | 1.153 | algemeen | neu | |
| 9.0 [8.5–9.6] | 1.101 | algemeen | neu | |
| 37.8 [32.8–43.6] | 213 | algemeen | neu | |
| 36.8 [35.7–37.9] | 5.004 | algemeen | neu | |
| 6.2 [5.5–7.0] | 255 | algemeen | neu | |
| 5.8 [5.1–6.6] | 255 | algemeen | neu | |
| 10.0 [8.6–11.6] | 174 | algemeen | neu | |
| 10.4 [8.7–12.5] | 126 | algemeen | neu | |
| 3.5 [2.4–5.0] | 29 | algemeen | neu | |
| 6.4 [5.6–7.3] | 207 | algemeen | neu | |
| 5.1 [4.4–5.8] | 209 | algemeen | neu | |
| 11.6 [10.4–13.0] | 321 | algemeen | neu | |
| 4.0 [3.4–4.6] | 189 | algemeen | neu | |
| 10.4 [9.9–11.0] | 1.303 | algemeen | neu | |
| 9.2 [8.6–9.9] | 841 | algemeen | neu | |
| 15.5 [12.8–18.8] | 110 | algemeen | neu | |
| 15.2 [12.8–18.1] | 135 | algemeen | neu | |
| 7.8 [6.1–9.9] | 69 | algemeen | neu | |
| 6.2 [2.3–16.7] | 4 | algemeen | neu | |
gold — | 36.2 [33.4–39.2] | 675 | algemeen | neu |
| 5.8 [5.2–6.4] | 315 | algemeen | neu | |
| 28.8 [25.1–33.0] | 224 | algemeen | neu | |
| 28.3 [24.6–32.4] | 224 | algemeen | neu | |
| 3.9 [3.4–4.3] | 303 | algemeen | neu | |
| 13.1 [11.2–15.2] | 171 | algemeen | neu | |
| 3.8 [2.7–5.2] | 35 | algemeen | neu | |
| 11.7 [10.3–13.4] | 226 | algemeen | neu | |
| 9.2 [8.9–9.5] | 3.294 | algemeen | neu | |
| 8.4 [8.1–8.7] | 3.318 | algemeen | neu | |
| 10.3 [9.8–10.8] | 1.935 | algemeen | neu | |
| 6.4 [6.1–6.6] | 2.041 | algemeen | neu | |
| 13.7 [13.0–14.4] | 1.529 | algemeen | neu | |
| 9.4 [9.0–9.8] | 2.509 | algemeen | neu | |
| 6.4 [5.3–7.7] | 118 | algemeen | neu | |
| 11.8 [10.7–12.9] | 429 | algemeen | neu | |
| 7.5 [6.8–8.4] | 351 | algemeen | neu | |
| 7.5 [6.7–8.3] | 347 | algemeen | neu | |
| 7.5 [6.7–8.3] | 347 | algemeen | neu | |
| 9.5 [8.3–10.9] | 224 | algemeen | neu | |
| 9.5 [8.3–10.9] | 224 | algemeen | neu | |
| 11.3 [10.8–11.9] | 1.937 | algemeen | neu | |
| 7.0 [5.8–8.5] | 105 | algemeen | neu | |
| 4.7 [4.3–5.3] | 343 | algemeen | neu | |
| 11.8 [10.7–12.9] | 429 | algemeen | neu | |
| 3.2 [2.4–4.2] | 47 | algemeen | neu | |
| 3.2 [2.4–4.2] | 48 | algemeen | neu | |
| 4.3 [3.5–5.3] | 98 | algemeen | neu | |
| 17.1 [15.1–19.4] | 263 | algemeen | neu | |
| 3.2 [2.1–5.1] | 19 | algemeen | neu | |
| 73.7 [60.0–90.5] | 114 | algemeen | neu | |
| 7.0 [6.1–8.0] | 219 | algemeen | neu | |
| 11.7 [10.6–12.9] | 429 | algemeen | neu | |
| 10.7 [9.7–11.7] | 433 | algemeen | neu | |
| 73.9 [70.7–77.2] | 2.587 | algemeen | neu | |
| 22.6 [18.1–28.3] | 83 | algemeen | neu | |
| 16.0 [13.7–18.7] | 173 | algemeen | neu | |
| 5.9 [5.3–6.6] | 302 | algemeen | neu | |
| 6.6 [5.8–7.4] | 272 | algemeen | neu | |
| 154.2 [113.4–209.6] | 62 | algemeen | neu | |
| 4.1 [3.1–5.5] | 44 | algemeen | neu | |
| 8.7 [7.5–10.1] | 189 | algemeen | neu | |
| 9.9 [9.5–10.3] | 2.960 | algemeen | neu | |
| 8.7 [8.4–9.0] | 4.333 | algemeen | neu | |
| 35.2 [30.6–40.6] | 215 | algemeen | neu | |
| 7.3 [6.5–8.2] | 305 | algemeen | neu | |
| 7.4 [6.6–8.2] | 305 | algemeen | neu | |
| 6.8 [6.1–7.6] | 310 | algemeen | neu | |
| 5.5 [4.9–6.1] | 291 | algemeen | neu | |
| 18.9 [16.7–21.4] | 263 | algemeen | neu | |
| 18.9 [16.7–21.4] | 263 | algemeen | neu | |
| 11.3 [10.2–12.6] | 357 | algemeen | neu | |
| 3.9 [3.5–4.5] | 246 | algemeen | neu | |
| 5.9 [5.5–6.3] | 775 | algemeen | neu | |
| 5.3 [4.2–6.7] | 70 | algemeen | neu | |
| 44.0 [39.1–49.5] | 318 | algemeen | neu | |
| 7.4 [7.0–7.7] | 2.084 | algemeen | neu | |
| 11.7 [9.5–14.3] | 93 | algemeen | neu | |
| 7.2 [5.8–8.8] | 93 | algemeen | neu | |
| 7.3 [6.2–8.6] | 147 | algemeen | neu | |
| 6.0 [5.1–6.9] | 169 | algemeen | neu | |
| 6.0 [5.1–7.0] | 171 | algemeen | neu | |
| 11.3 [9.8–12.9] | 216 | algemeen | neu | |
| 6.2 [6.0–6.4] | 5.548 | algemeen | neu | |
| 6.2 [6.0–6.3] | 5.557 | algemeen | neu | |
| 3.2 [2.4–4.2] | 47 | algemeen | neu | |
| 7.4 [5.2–10.6] | 31 | algemeen | neu | |
| 16.8 [15.0–18.7] | 340 | algemeen | neu | |
| 2.9 [2.6–3.4] | 206 | algemeen | neu | |
| 3.2 [2.8–3.7] | 180 | algemeen | neu |
ROR = Reporting Odds Ratio gegenüber dem gesamten FAERS-Korpus. Ein Signal ist keine Ursache. Quelle: openFDA (FAERS).